Quote | TPG Inc. (NASDAQ:TPG)
Last: | $40.64 |
---|---|
Change Percent: | 0.0% |
Open: | $41.13 |
Close: | $40.64 |
High: | $41.13 |
Low: | $40.26 |
Volume: | 941,320 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | TPG Inc. (NASDAQ:TPG)
2024-06-28 08:12:47 ET More on Boat Rocker Media, TPG TPG Inc. (TPG) Q1 2024 Earnings Call Transcript BlackRock, Blackstone, TPG best positioned to navigate AI watershed, analyst says TPG raised to Overweight at Morgan Stanley on capital markets rebound (updated) ...
Announces First Investment in Leading Hollywood Management Company Untitled Entertainment TPG (NASDAQ: TPG), a leading global alternative asset management firm, today announced the formation of a new company (the “Company”) that will acquire, invest behind, and build a...
Message Board Posts | TPG Inc. (NASDAQ:TPG)
Subject | By | Source | When |
---|---|---|---|
Heres a breakdown of dual listing per otcmarkets | Pro-Life | investorshub | 06/22/2021 3:36:13 PM |
https://www2.asx.com.au/listings/how-to-list/listing-requirements | Pro-Life | investorshub | 06/22/2021 3:36:07 PM |
The New Unrealized Capital Gains Tax / The | Pro-Life | investorshub | 03/12/2021 6:16:56 AM |
Fail... | Pro-Life | investorshub | 03/09/2021 10:32:20 PM |
https://www.investorshub.advfn.com/uimage/uploads/2021/3/9/wbmspCapture.JPG | Pro-Life | investorshub | 03/09/2021 10:31:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Announces First Investment in Leading Hollywood Management Company Untitled Entertainment TPG (NASDAQ: TPG), a leading global alternative asset management firm, today announced the formation of a new company (the “Company”) that will acquire, invest behind, and build a...
BOAT ROCKER SELLS MAJORITY STAKE IN UNTITLED ENTERTAINMENT TO LEADING GLOBAL ALTERNATIVE ASSET MANAGER TPG Canada NewsWire Boat Rocker to Receive 8.8 % in TPG's New Talent Management and Representation Company Boat Rocker Provides Updated 2024 Outlook M...
TPG (NASDAQ: TPG), a leading global alternative asset management firm, today announced a significant strategic growth investment in K2 Medical Research (“K2” or the “Company”), an integrated clinical trial site platform specializing in central nervous system (CNS) tria...